Definitive Contract 75N93023C00048

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6.9 million definitive contract on September 30, 2023, to Institut De Formulation DES Vaccins (Ch) SA, operating as Vaccine Formulation Institute (Ch) LTD, a Switzerland-based nonprofit organization specializing in vaccine adjuvant development. Under this firm fixed-price contract, the awardee will conduct advanced development of a liposome-based saponin-containing adjuvant designed for use in pan-sarbecovirus vaccines. The contract, which carries no set-aside designation, is scheduled for completion by September 30, 2026, and represents a critical investment in vaccine technology aimed at addressing emerging viral threats through enhanced adjuvant formulations that improve immune response.

The Vaccine Formulation Institute brings substantial expertise to this effort, having previously secured a larger NIAID contract valued at $9.2 million for the broader Vaccine Adjuvant Discovery Program. The institute's specialized capabilities in formulation optimization, adjuvant characterization, and manufacturing, combined with its demonstrated track record in supporting both federal contracts and collaborative research initiatives, position it as a key contributor to NIAID's vaccine development objectives. This contract aligns with the agency's mission to accelerate vaccine innovation and improve public health preparedness for pandemic-prone pathogens.